Schlesinger: For advanced cSCC, immunotherapy has been a game-changer. The first immunotherapy drugs approved in the space ...

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report offers exhaustive insights into ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ...

PD-1/PD-L1 Checkpoint Inhibitors Market · GlobeNewswire Inc. Dublin, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The "PD-1/PD-L1 Checkpoint Inhibitors Market - Global Forecast 2026-2032" report has been added ...

The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...

Effect of multifunctional biocatalytic nanoenzyme AuC@SCOF-Mn on photodynamic-immunoactivation cascade response and antitumor efficacy in triple negative breast cancer. This is an ASCO Meeting ...

Significant PFS and OS Improvement: Among PD-L1-low patients, the cadonilimab group achieved a median OS of 14.3 months, significantly longer than the 10.3 months observed in the PD-1 inhibitor group ...